Laman UtamaLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
$0.62
Selepas Waktu Dagangan:(0.00%)0.00
$0.62
Tutup: 27 Jan, 4:02:31 PTG GMT-5 · USD · NYSEAMERICAN · Penafian
Tutup sebelumnya
$0.64
Julat hari
$0.60 - $0.65
Julat tahun
$0.48 - $1.61
Permodalan pasaran
136.64J USD
Bilangan Purata
2.54J
Nisbah P/E
-
Hasil dividen
-
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 3.78J | 203.29% |
Perbelanjaan pengendalian | 4.41J | 9.13% |
Pendapatan bersih | -3.03J | 57.33% |
Margin untung bersih | -80.29 | 85.93% |
Pendapatan bagi setiap syer | -0.02 | 50.37% |
EBITDA | -3.70J | 43.35% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 32.71J | -20.86% |
Jumlah aset | 96.59J | -9.00% |
Jumlah liabiliti | 31.80J | -19.48% |
Jumlah ekuiti | 64.79J | — |
Syer tertunggak | 188.84J | — |
Harga kepada buku | 1.82 | — |
Pulangan pada aset | -9.63% | — |
Pulangan pada modal | -13.98% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -3.03J | 57.33% |
Tunai daripada operasi | -5.79J | -14.89% |
Tunai daripada pelaburan | 3.89J | 83.22% |
Tunai daripada pembiayaan | -3.00K | -100.37% |
Perubahan bersih dalam tunai | -1.86J | 23.86% |
Aliran tunai bebas | -2.27J | 12.27% |
Perihal
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Diasaskan
1990
Tapak web
Pekerja
72